What question did this study set out to answer?

The study aims to determine if the CHA2DS2-VASc score independently predicts high thrombus burden and mortality in ACS patients with COVID-19.

February 5, 2026Open Access

The Surrogate Marker for Coronary Thrombus Burden in Acute Coronary Syndrome Patients with COVID-19: The CHA2DS2-VASc Score

Key Points

The study aims to determine if the CHA2DS2-VASc score independently predicts high thrombus burden and mortality in ACS patients with COVID-19.
Included 76 ACS patients with COVID-19
Grouped patients into low thrombus burden and high thrombus burden based on thrombus scores
Compared CHA2DS2-VASc scores between the two groups
65.7% of patients developed high thrombus burden post-procedure
Significant difference found in neutrophil to lymphocyte ratios between groups

Abstract

Background: This study investigated whether CHA2DS2-VASc score is an independent predictor of high thrombus burden and mortality in patients presenting with acute coronary syndrome (ACS) with Coronavirus disease (COVID-19). Material Method: Patients with ACS (n=76) with COVID-19 were included in the study. The patients were grouped into low thrombus burden (LTB) (grades 1–3) and high-thrombus burden (HTB) groups (grades 4 and 5) according to the final thrombus score. CHA2DS2-VASc scores were compared between the two groups. Result: Postpocedural HTB developed in 50 (65.7%) patients. Neutrophile to lymphocyte ratio (6.00 ± 3.73 vs 11.45 ± 10.6), P

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper